Scan results and possible options…

Kevin,

Consider this trial perhaps…

This is the sister trial of mine…the 4,5,and 6 arm allows for previous use of Anti PD 1

Phase I Pilot Study of Peptide Vaccine Comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 Emulsified in Montanide ISA 51 VG and Anti-PD-1 Human Monoclonal Antibody MDX-1106 in Patients With Unresectable Stage III or IV Melanoma

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Basic Trial Information

Objectives

Primary

1. To assess the safety and tolerability of multiple class I peptide vaccine comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 emulsified in Montanide ISA 51 VG and anti-PD-1 human monoclonal antibody MDX-1106 (BMS-936558) in HLA-A*0201-positive patients with unresectable stage III or IV malignant melanoma (patients in cohort 6 will not be HLA restricted).

Secondary

1. To evaluate the immune response at week 12 in patients treated with these regimens compared to the immune response to peptide vaccine alone that was determined in previous studies.
2. To assess the host immune response (immunogenicity) to BMS-936558.
3. To assess, preliminarily, the efficacy of these regimens in these patients.

Entry Criteria

Disease Characteristics:

• Histologically confirmed melanoma
  • Unresectable stage III or IV disease
  • HLA-A*0201 positive by DNA allele-specific PCR assay (not a requirement for cohort 6)

   

• Positive staining of tumor tissue for ≥ 1 of the following: antibody HMB-45 for gp100, NY-ESO-1, and/or MART-1

   

• At least 1 measurable lesion

   

• Must have failed ≥ 1 chemotherapy regimen for metastatic disease

   

• Must have failed prior ipilimumab (cohorts 4, 5, and 6)

   

• Prior treated brain and meningeal metastases allowed provided the following criteria are met:
  • No evidence of progression by MRI within the past 8 weeks
  • Off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for ≥ 2 weeks

   

Prior/Concurrent Therapy:

• See Disease Characteristics
• May have received ≤ 2 prior chemotherapy regimens
• At least 4 weeks since prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) and recovered
• At least 2 weeks since prior immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (> 10 mg/day prednisone or equivalent)
• At least 4 weeks since prior systemic radiotherapy
  • At least 2 weeks since prior focal radiotherapy
  • More than 8 weeks since prior radiopharmaceuticals (strontium, samarium)
• At least 6 weeks since prior nitrosourea
• At least 2 weeks since prior surgery that required general anesthesia
  • At least 72 hours since prior surgery requiring local and/or epidural anesthesia
• No prior anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
• No concurrent participation in another clinical study involving treatment with medications, radiotherapy, or surgery or prior participation in this study
• No concurrent use of any of the following:
  • Other anticancer agents
  • Immunosuppressive agents
  • Immunosuppressive doses of systemic or topical steroids whose absorption is expected to result in systemically immunosuppressive steroid levels
  • Non-oncologic vaccines (during and ≥ 4 weeks after study treatment)
• Patients in the fourth cohort must meet the following criteria:
  • Ipilimumab at 3 mg/kg must have been completed not less than 4 weeks prior to initiation of anti-PD-1 human monoclonal antibody MDX-1106 (MDX-1106)
  • Ipilimumab at 10 mg/kg must have been completed not less than 6 weeks prior to initiation of MDX-1106
  • All drug-related toxicities must have resolved to grade 1 or less or non-DLT grade 2
  • Patients must be off steroids for at least 3 weeks
  • No patients who required infliximab or other immune suppressants including mycophenolic acid
• Patients in the fifth and sixth cohort must meet the following criteria:
  • Ipilimumab at 3 mg/kg or 10 mg/kg must have been completed not less than 8 weeks prior to initiation of MDX-1106
  • All drug-related toxicities must have resolved to grade 1 or less or non-DLT grade 2
  • Patients must be off steroids for at least 3 weeks
  • No patients who required infliximab or other immune suppressants including mycophenolic acid

Patient Characteristics:

• ECOG performance status 0-1
• Life expectancy ≥ 3 months
• WBC ≥ 2,000/μL
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Hemoglobin ≥ 9.0 g/dL
• Serum creatinine ≤ 2 mg/dL
• AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for hepatic metastasis)
• Bilirubin ≤ 2 times ULN (< 3 times ULN for patients with Gilbert syndrome)
• Fertile patients must agree to use effective contraception for ≥ 28 days before, during, and for ≥ 70 days (180 days for males) after completion of treatment period
• Negative pregnancy test
• Not pregnant or nursing
• Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol
• No history of severe hypersensitivity reactions to other monoclonal antibodies
• No systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
• No active malignancy within the past 2 years except for curatively treated local cancer, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
• No prior or active autoimmune disease, or history of syndrome requiring systemic steroids or immunosuppressive medications
  • Patients with vitiligo or resolved childhood asthma and/or atopy allowed
• No known HIV positivity or AIDS
• Not positive for hepatitis B virus surface antigen or hepatitis C virus RNA indicating active or chronic infection
• No underlying medical condition (e.g., a condition associated with diarrhea) that, in the investigator's opinion, would make the administration of any of the study drugs hazardous to the patient, or obscure the interpretation of toxicity determination or adverse events
• No concurrent medical condition requiring the use of immunosuppressive doses of systemic or absorbable topical corticosteroids

Expected Enrollment

85

Outcomes

Primary Outcome(s)

Best overall response (complete or partial response, stable disease, or progressive disease)
Adverse events

Secondary Outcome(s)

Time to response
Duration of response

Outline

This is a dose-escalation study of anti-PD-1 human monoclonal antibody MDX-1106.

Patients receive peptide vaccines* comprising gp 100 (210M), MART-1 (27L), gp100 (288V), and NY-ESO-1(165V) emulsified by Montanide ISA 51 VG subcutaneously and anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes once a week on weeks 1, 3, 5, 7, 9, and 11. Treatment repeats every 12 weeks for 2 courses. Patients with responsive or stable disease continue to receive anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

[Note: *Patients in cohorts 1-5 will receive the peptide vaccine, but not those in cohort 6.]

Blood samples are collected for pharmacokinetic and immunologic analysis.

After completion of study therapy, patients are followed up periodically for 2 years.

Trial Contact Information

Trial Lead Organizations

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

Jeffrey Weber, MD, PhD, Principal investigator		Ph: 813-747-2691; 888-663-3488

Trial Sites

U.S.A.
Florida
	Tampa
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
		Clinical Trials Office – H. Lee Moffitt Cancer Center and Reseach Institute	Ph: 800-456-7121
			Email: canceranswers@moffitt.org

See All Trial Sites

		NCT01176461
Date Submitted to PDQ		2010-08-02
Information Last Verified		2012-02-14
NCI Grant/Contract Number		CA-129594

Kevin,

Consider this trial perhaps…

This is the sister trial of mine…the 4,5,and 6 arm allows for previous use of Anti PD 1

Phase I Pilot Study of Peptide Vaccine Comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 Emulsified in Montanide ISA 51 VG and Anti-PD-1 Human Monoclonal Antibody MDX-1106 in Patients With Unresectable Stage III or IV Melanoma

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Basic Trial Information

Objectives

Primary

1. To assess the safety and tolerability of multiple class I peptide vaccine comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 emulsified in Montanide ISA 51 VG and anti-PD-1 human monoclonal antibody MDX-1106 (BMS-936558) in HLA-A*0201-positive patients with unresectable stage III or IV malignant melanoma (patients in cohort 6 will not be HLA restricted).

Secondary

1. To evaluate the immune response at week 12 in patients treated with these regimens compared to the immune response to peptide vaccine alone that was determined in previous studies.
2. To assess the host immune response (immunogenicity) to BMS-936558.
3. To assess, preliminarily, the efficacy of these regimens in these patients.

Entry Criteria

Disease Characteristics:

• Histologically confirmed melanoma
  • Unresectable stage III or IV disease
  • HLA-A*0201 positive by DNA allele-specific PCR assay (not a requirement for cohort 6)

   

• Positive staining of tumor tissue for ≥ 1 of the following: antibody HMB-45 for gp100, NY-ESO-1, and/or MART-1

   

• At least 1 measurable lesion

   

• Must have failed ≥ 1 chemotherapy regimen for metastatic disease

   

• Must have failed prior ipilimumab (cohorts 4, 5, and 6)

   

• Prior treated brain and meningeal metastases allowed provided the following criteria are met:
  • No evidence of progression by MRI within the past 8 weeks
  • Off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for ≥ 2 weeks

   

Prior/Concurrent Therapy:

• See Disease Characteristics
• May have received ≤ 2 prior chemotherapy regimens
• At least 4 weeks since prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) and recovered
• At least 2 weeks since prior immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (> 10 mg/day prednisone or equivalent)
• At least 4 weeks since prior systemic radiotherapy
  • At least 2 weeks since prior focal radiotherapy
  • More than 8 weeks since prior radiopharmaceuticals (strontium, samarium)
• At least 6 weeks since prior nitrosourea
• At least 2 weeks since prior surgery that required general anesthesia
  • At least 72 hours since prior surgery requiring local and/or epidural anesthesia
• No prior anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
• No concurrent participation in another clinical study involving treatment with medications, radiotherapy, or surgery or prior participation in this study
• No concurrent use of any of the following:
  • Other anticancer agents
  • Immunosuppressive agents
  • Immunosuppressive doses of systemic or topical steroids whose absorption is expected to result in systemically immunosuppressive steroid levels
  • Non-oncologic vaccines (during and ≥ 4 weeks after study treatment)
• Patients in the fourth cohort must meet the following criteria:
  • Ipilimumab at 3 mg/kg must have been completed not less than 4 weeks prior to initiation of anti-PD-1 human monoclonal antibody MDX-1106 (MDX-1106)
  • Ipilimumab at 10 mg/kg must have been completed not less than 6 weeks prior to initiation of MDX-1106
  • All drug-related toxicities must have resolved to grade 1 or less or non-DLT grade 2
  • Patients must be off steroids for at least 3 weeks
  • No patients who required infliximab or other immune suppressants including mycophenolic acid
• Patients in the fifth and sixth cohort must meet the following criteria:
  • Ipilimumab at 3 mg/kg or 10 mg/kg must have been completed not less than 8 weeks prior to initiation of MDX-1106
  • All drug-related toxicities must have resolved to grade 1 or less or non-DLT grade 2
  • Patients must be off steroids for at least 3 weeks
  • No patients who required infliximab or other immune suppressants including mycophenolic acid

Patient Characteristics:

• ECOG performance status 0-1
• Life expectancy ≥ 3 months
• WBC ≥ 2,000/μL
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Hemoglobin ≥ 9.0 g/dL
• Serum creatinine ≤ 2 mg/dL
• AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for hepatic metastasis)
• Bilirubin ≤ 2 times ULN (< 3 times ULN for patients with Gilbert syndrome)
• Fertile patients must agree to use effective contraception for ≥ 28 days before, during, and for ≥ 70 days (180 days for males) after completion of treatment period
• Negative pregnancy test
• Not pregnant or nursing
• Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol
• No history of severe hypersensitivity reactions to other monoclonal antibodies
• No systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
• No active malignancy within the past 2 years except for curatively treated local cancer, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
• No prior or active autoimmune disease, or history of syndrome requiring systemic steroids or immunosuppressive medications
  • Patients with vitiligo or resolved childhood asthma and/or atopy allowed
• No known HIV positivity or AIDS
• Not positive for hepatitis B virus surface antigen or hepatitis C virus RNA indicating active or chronic infection
• No underlying medical condition (e.g., a condition associated with diarrhea) that, in the investigator's opinion, would make the administration of any of the study drugs hazardous to the patient, or obscure the interpretation of toxicity determination or adverse events
• No concurrent medical condition requiring the use of immunosuppressive doses of systemic or absorbable topical corticosteroids

Expected Enrollment

85

Outcomes

Primary Outcome(s)

Best overall response (complete or partial response, stable disease, or progressive disease)
Adverse events

Secondary Outcome(s)

Time to response
Duration of response

Outline

This is a dose-escalation study of anti-PD-1 human monoclonal antibody MDX-1106.

Patients receive peptide vaccines* comprising gp 100 (210M), MART-1 (27L), gp100 (288V), and NY-ESO-1(165V) emulsified by Montanide ISA 51 VG subcutaneously and anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes once a week on weeks 1, 3, 5, 7, 9, and 11. Treatment repeats every 12 weeks for 2 courses. Patients with responsive or stable disease continue to receive anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

[Note: *Patients in cohorts 1-5 will receive the peptide vaccine, but not those in cohort 6.]

Blood samples are collected for pharmacokinetic and immunologic analysis.

After completion of study therapy, patients are followed up periodically for 2 years.

Trial Contact Information

Trial Lead Organizations

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

Jeffrey Weber, MD, PhD, Principal investigator		Ph: 813-747-2691; 888-663-3488

Trial Sites

U.S.A.
Florida
	Tampa
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
		Clinical Trials Office – H. Lee Moffitt Cancer Center and Reseach Institute	Ph: 800-456-7121
			Email: canceranswers@moffitt.org

See All Trial Sites

		NCT01176461
Date Submitted to PDQ		2010-08-02
Information Last Verified		2012-02-14
NCI Grant/Contract Number		CA-129594

Correction  Previous USE of IPI!! I need SLEEP!! Long Day at Disney World today!

Correction  Previous USE of IPI!! I need SLEEP!! Long Day at Disney World today!

Correction  Previous USE of IPI!! I need SLEEP!! Long Day at Disney World today!

Kevin,

Consider this trial perhaps…

This is the sister trial of mine…the 4,5,and 6 arm allows for previous use of Anti PD 1

Phase I Pilot Study of Peptide Vaccine Comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 Emulsified in Montanide ISA 51 VG and Anti-PD-1 Human Monoclonal Antibody MDX-1106 in Patients With Unresectable Stage III or IV Melanoma

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Basic Trial Information

Objectives

Primary

1. To assess the safety and tolerability of multiple class I peptide vaccine comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 emulsified in Montanide ISA 51 VG and anti-PD-1 human monoclonal antibody MDX-1106 (BMS-936558) in HLA-A*0201-positive patients with unresectable stage III or IV malignant melanoma (patients in cohort 6 will not be HLA restricted).

Secondary

1. To evaluate the immune response at week 12 in patients treated with these regimens compared to the immune response to peptide vaccine alone that was determined in previous studies.
2. To assess the host immune response (immunogenicity) to BMS-936558.
3. To assess, preliminarily, the efficacy of these regimens in these patients.

Entry Criteria

Disease Characteristics:

• Histologically confirmed melanoma
  • Unresectable stage III or IV disease
  • HLA-A*0201 positive by DNA allele-specific PCR assay (not a requirement for cohort 6)

   

• Positive staining of tumor tissue for ≥ 1 of the following: antibody HMB-45 for gp100, NY-ESO-1, and/or MART-1

   

• At least 1 measurable lesion

   

• Must have failed ≥ 1 chemotherapy regimen for metastatic disease

   

• Must have failed prior ipilimumab (cohorts 4, 5, and 6)

   

• Prior treated brain and meningeal metastases allowed provided the following criteria are met:
  • No evidence of progression by MRI within the past 8 weeks
  • Off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for ≥ 2 weeks

   

Prior/Concurrent Therapy:

• See Disease Characteristics
• May have received ≤ 2 prior chemotherapy regimens
• At least 4 weeks since prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) and recovered
• At least 2 weeks since prior immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (> 10 mg/day prednisone or equivalent)
• At least 4 weeks since prior systemic radiotherapy
  • At least 2 weeks since prior focal radiotherapy
  • More than 8 weeks since prior radiopharmaceuticals (strontium, samarium)
• At least 6 weeks since prior nitrosourea
• At least 2 weeks since prior surgery that required general anesthesia
  • At least 72 hours since prior surgery requiring local and/or epidural anesthesia
• No prior anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
• No concurrent participation in another clinical study involving treatment with medications, radiotherapy, or surgery or prior participation in this study
• No concurrent use of any of the following:
  • Other anticancer agents
  • Immunosuppressive agents
  • Immunosuppressive doses of systemic or topical steroids whose absorption is expected to result in systemically immunosuppressive steroid levels
  • Non-oncologic vaccines (during and ≥ 4 weeks after study treatment)
• Patients in the fourth cohort must meet the following criteria:
  • Ipilimumab at 3 mg/kg must have been completed not less than 4 weeks prior to initiation of anti-PD-1 human monoclonal antibody MDX-1106 (MDX-1106)
  • Ipilimumab at 10 mg/kg must have been completed not less than 6 weeks prior to initiation of MDX-1106
  • All drug-related toxicities must have resolved to grade 1 or less or non-DLT grade 2
  • Patients must be off steroids for at least 3 weeks
  • No patients who required infliximab or other immune suppressants including mycophenolic acid
• Patients in the fifth and sixth cohort must meet the following criteria:
  • Ipilimumab at 3 mg/kg or 10 mg/kg must have been completed not less than 8 weeks prior to initiation of MDX-1106
  • All drug-related toxicities must have resolved to grade 1 or less or non-DLT grade 2
  • Patients must be off steroids for at least 3 weeks
  • No patients who required infliximab or other immune suppressants including mycophenolic acid

Patient Characteristics:

• ECOG performance status 0-1
• Life expectancy ≥ 3 months
• WBC ≥ 2,000/μL
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Hemoglobin ≥ 9.0 g/dL
• Serum creatinine ≤ 2 mg/dL
• AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for hepatic metastasis)
• Bilirubin ≤ 2 times ULN (< 3 times ULN for patients with Gilbert syndrome)
• Fertile patients must agree to use effective contraception for ≥ 28 days before, during, and for ≥ 70 days (180 days for males) after completion of treatment period
• Negative pregnancy test
• Not pregnant or nursing
• Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol
• No history of severe hypersensitivity reactions to other monoclonal antibodies
• No systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
• No active malignancy within the past 2 years except for curatively treated local cancer, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
• No prior or active autoimmune disease, or history of syndrome requiring systemic steroids or immunosuppressive medications
  • Patients with vitiligo or resolved childhood asthma and/or atopy allowed
• No known HIV positivity or AIDS
• Not positive for hepatitis B virus surface antigen or hepatitis C virus RNA indicating active or chronic infection
• No underlying medical condition (e.g., a condition associated with diarrhea) that, in the investigator's opinion, would make the administration of any of the study drugs hazardous to the patient, or obscure the interpretation of toxicity determination or adverse events
• No concurrent medical condition requiring the use of immunosuppressive doses of systemic or absorbable topical corticosteroids

Expected Enrollment

85

Outcomes

Primary Outcome(s)

Best overall response (complete or partial response, stable disease, or progressive disease)
Adverse events

Secondary Outcome(s)

Time to response
Duration of response

Outline

This is a dose-escalation study of anti-PD-1 human monoclonal antibody MDX-1106.

Patients receive peptide vaccines* comprising gp 100 (210M), MART-1 (27L), gp100 (288V), and NY-ESO-1(165V) emulsified by Montanide ISA 51 VG subcutaneously and anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes once a week on weeks 1, 3, 5, 7, 9, and 11. Treatment repeats every 12 weeks for 2 courses. Patients with responsive or stable disease continue to receive anti-PD-1 human monoclonal antibody MDX-1106 IV over 60 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

[Note: *Patients in cohorts 1-5 will receive the peptide vaccine, but not those in cohort 6.]

Blood samples are collected for pharmacokinetic and immunologic analysis.

After completion of study therapy, patients are followed up periodically for 2 years.

Trial Contact Information

Trial Lead Organizations

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

Jeffrey Weber, MD, PhD, Principal investigator		Ph: 813-747-2691; 888-663-3488

Trial Sites

U.S.A.
Florida
	Tampa
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
		Clinical Trials Office – H. Lee Moffitt Cancer Center and Reseach Institute	Ph: 800-456-7121
			Email: canceranswers@moffitt.org

See All Trial Sites

		NCT01176461
Date Submitted to PDQ		2010-08-02
Information Last Verified		2012-02-14
NCI Grant/Contract Number		CA-129594

I have been thinking and praying for you.  Good for you for getting all your information off as soon as possible and I am hopeful they can find a plan for you and can take you.   

The positive news is there seems to be more and more trials coming out and one of them will be the winner for you, you are young and strong and such an amazing attitude!!.  I do hope the yervoy is just taking it time and will kick in for you.

take care, keep us posted, stay strong!

laurie from maine

I have been thinking and praying for you.  Good for you for getting all your information off as soon as possible and I am hopeful they can find a plan for you and can take you.   

The positive news is there seems to be more and more trials coming out and one of them will be the winner for you, you are young and strong and such an amazing attitude!!.  I do hope the yervoy is just taking it time and will kick in for you.

take care, keep us posted, stay strong!

laurie from maine

I have been thinking and praying for you.  Good for you for getting all your information off as soon as possible and I am hopeful they can find a plan for you and can take you.   

The positive news is there seems to be more and more trials coming out and one of them will be the winner for you, you are young and strong and such an amazing attitude!!.  I do hope the yervoy is just taking it time and will kick in for you.

take care, keep us posted, stay strong!

laurie from maine

Kevin,

I forgot one thing. If you do BRAF, try to get it in combination with MEK inhibitor.  Melanoma seems to find its way around the Braf pathway. So blocking both pathways lowers the chances that Melanoma will circumvent the pathways.

Best regards,

Jimmy B

Kevin,

I forgot one thing. If you do BRAF, try to get it in combination with MEK inhibitor.  Melanoma seems to find its way around the Braf pathway. So blocking both pathways lowers the chances that Melanoma will circumvent the pathways.

Best regards,

Jimmy B

Kevin,

I forgot one thing. If you do BRAF, try to get it in combination with MEK inhibitor.  Melanoma seems to find its way around the Braf pathway. So blocking both pathways lowers the chances that Melanoma will circumvent the pathways.

Best regards,

Jimmy B